

Regulatory Announcement

Go to market news section

Company	FuturaGene PLC
TIDM	FGN
Headline	Directorate Change
Released	16:54 06-Jul-05

FuturaGene PLC

FuturaGene Announces the Appointment of Kannan grant as an Executive Director with Responsibility for Licensing and Joint Ventures

FuturaGene Plc, which develops environmentally friendly solutions to allow crops to grow in extreme conditions, is pleased to announce the appointment of Mr Kannan Grant as an executive director. Mr Grant will be responsible for strategic alliances, partnerships, mergers, and acquisitions. He was appointed a non-executive director on 21 September 2004.

Mr Grant recently held the position of Associate Vice Chancellor for Technology Development at the University of Nebraska, USA, and has over ten years experience in the commercialisation of university generated technology.

‘We are delighted Kannan is becoming an executive director,’ said Mark Pritchard, FuturaGene’s chairman. ‘With his background in commercialising research from universities, he will play an important role in enabling FuturaGene achieve its ambition in structuring deals with its major commercial partners.’

Mr Grant, aged 41, does not hold any other directorships and there is no further information to be disclosed in accordance with the AIM rules.

ENDS

For further information, please contact:

FuturaGene Plc	
Mark Pritchard, Chairman	+44 (0) 7802 827 846

Cubitt Consulting	
Michael Henman	+44 (0) 20 7367 5100

Notes to Editors

1. FuturaGene Plc

FuturaGene is committed to the research and development of environmentally friendly solutions to solve crop production problems.

FuturaGene Plc. Is a British company, that sponsors research at a consortium of universities to develop knowledge and create intellectual property that is essential to the development of crop species with enhanced agronomic characteristics including tolerance to a variety of environmental stress such as salt, drought and cold conditions.

FuturaGene has established contracts with several universities for the exclusive global commercial rights on a suite of utility and provisional patents.

The Group's technology comprises of a licensed patented portfolio of genes which enhance the function of genes already present in the plant through over expression of these genes. FuturaGene has identified genes which confer enhanced tolerance and enable plants to withstand extreme environmental stresses such as cold, drought, fungal pathogens and high salt concentrations.

FuturaGene already has laboratory prototypes of rice and tomato plants with resistance to salt, drought and cold. Selected field tests are planned shortly.

The total seed agricultural biotechnology market is estimated to have a value in the region of \$3bn. The demand for transgenic seeds, such as FuturaGene's, is estimated to grow at some 12% through to 2006, while the total seeds market is estimated to be worth between \$12 and \$15 bn

FuturaGene was admitted to AIM (London's Alternative Investment Market) in May 2004.